News
List of company announcements and press releases.
Click here for announcements regarding managers transactions.
Click here for news in Danish.
June 26, 2024 | Company Announcements
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMAJune 17, 2024 | Company Announcements
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate May 31, 2024 | Company Announcements
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox VaccineMay 22, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMay 21, 2024 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 21, 2024 | Company Announcements
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian NordicMay 08, 2024 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 08, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2024April 29, 2024 | Company Announcements
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic ReserveApril 29, 2024 | Company Announcements
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate April 16, 2024 | Company Announcements
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SMarch 21, 2024 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General MeetingMarch 06, 2024 | Company Announcements
Bavarian Nordic Publishes Annual Report 2023February 23, 2024 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines AgencyFebruary 21, 2024 | Company Announcements
Bavarian Nordic delivered record financial results in 2023December 13, 2023 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 30, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 16, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023October 25, 2023 | Company Announcements
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at RiskSeptember 04, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchSeptember 01, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchAugust 31, 2023 | Company Announcements
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine ProgramAugust 23, 2023 | Company Announcements
Bavarian Nordic Announces First Half 2023 ResultsAugust 06, 2023 | Company Announcements
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents August 03, 2023 | Company Announcements
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government